Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesImmunology/RheumatologyAmeriHealth Caritas autoimmune panel coverage | Op…
    Ask Trek AI about this page
    CurrentAmeriHealth CaritasPolicy CCP.1562

    Autoimmune disease diagnostic panel testing

    Customize your policy alerts

    Sign up for AmeriHealth Caritas Policy CCP.1562 alerts

    Get alerted when Policy CCP.1562 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage for blood-based multianalyte and proprietary algorithm autoimmune diagnostic panels (including AVISE-type tests and cell-bound complement activation product panels) for diagnosis, differentiation, prognosis, risk stratification, or management of systemic autoimmune diseases such as systemic lupus erythematosus (SLE). It affects AmeriHealth Caritas members and their providers seeking coverage for these tests.

    Policy Summary
    PayerAmeriHealth Caritas
    PolicyAutoimmune disease diagnostic panel testing
    Policy CodePolicy CCP.1562
    Change TypeNo material change
    Effective DateJul 1, 2026
    Next Review DateOct 1, 2027
    Key ActionExpect prior authorization requests for listed multianalyte/proprietary autoimmune panel codes to be denied as investigational/not medically necessary; document conventional serologic evaluation and clinical assessment when evaluating suspected systemic autoimmune disease.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Not medically necessarycoverage stance
    Policy createdpolicy status
    5tests listed

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    SLE
    primary condition

    Coverage Determination

    Not medically necessary (investigational) testing

    Covered when ALL of the following are met:

    Policy stance: Autoimmune disease diagnostic panel testing (including multianalyte assay panels, proprietary algorithm-based panels, AVISE-type tests, and cell-bound complement activation product panels) is investigational/not clinically proven and therefore not medically necessary for diagnosis, differentiation, prognosis, risk stratification, or management of autoimmune disease, including systemic lupus erythematosus and related connective tissue diseases.

    Direct statement of policy coverage stance from document.

    All uses of blood‑based autoimmune multianalyte and proprietary algorithm panels — including multianalyte assay panels, proprietary algorithm‑based panels, AVISE‑type tests, and cell‑bound complement activation product panels — for diagnosis, differentiation, prognosis, risk stratification, or management of autoimmune disease (including systemic lupus erythematosus and related connective tissue diseases) are addressed by this policy and are considered investigational/not medically necessary.

    Autoimmune disease diagnostic panel testing refers to blood‑based tests that combine multiple serum‑ or cell‑associated biomarkers with a proprietary interpretive score or algorithm. Examples include multianalyte assay panels, proprietary algorithm‑based autoimmune panels, AVISE‑type autoimmune diagnostic panels, and cell‑bound complement activation product panels. These tests generate composite or algorithmic risk or likelihood scores intended to support evaluation for suspected systemic autoimmune disease rather than replacing conventional serologic testing or clinical assessment.

    Related Codes

    Related codesmixed
    0062UAutoimmune (systemic lupus erythematosus), IgG and IgM analysis of 80 biomarkers, utilizing serum, algorithm reported with a risk score.
    0312UAutoimmune diseases (e.g., systemic lupus erythematosus [SLE]), analysis of 8 IgG autoantibodies and 2 cell-bound complement activation products using enzyme-linked immunosorbent immunoassay (ELISA), flow cytometry, and indirect immunofluorescence, serum, or plasma and whole blood, individual components reported along with an algorithmic SLE-likelihood assessment.
    0446UAutoimmune diseases (systemic lupus erythematosus [SLE]), analysis of 10 cytokine soluble mediator biomarkers by immunoassay, plasma, individual components reported with an algorithmic risk score for current disease activity.
    0447UAutoimmune diseases (systemic lupus erythematosus [SLE]), analysis of 11 cytokine soluble mediator biomarkers by immunoassay, plasma, individual components reported with an algorithmic prognostic risk score for developing a clinical flare.
    81599Unlisted multianalyte assay with algorithmic analysis.

    Provider Requirements and Administrative Actions

    Prior Authorization

    Prior authorization expected — listed codes are investigational

    Autoimmune multianalyte and proprietary algorithm panel testing identified by codes 0062U, 0312U, 0446U, 0447U, and 81599 are considered investigational and not medically necessary; prior authorization requests for these services are expected to be denied.

    • Codes listed as commonly submitted for these tests: 0062U, 0312U, 0446U, 0447U, 81599.
    Step Therapy

    No step therapy defined — investigational stance

    There are no step therapy protocols specified in this policy; the policy stance for the described autoimmune multianalyte/proprietary algorithm panels is investigational/not medically necessary.

    Background

    Multianalyte autoimmune diagnostic panels measure multiple biomarkers — serum or cell‑associated — and apply proprietary interpretive algorithms to produce composite scores or risk assessments intended to inform evaluation for systemic autoimmune diseases, primarily systemic lupus erythematosus. While these panels report individual components along with algorithmic outputs, conventional serologic testing (for example, ANA, anti‑dsDNA, anti‑Smith, complement proteins) and clinical assessment remain the basis for diagnosis. The rationale for the policy stance is that current evidence is limited regarding clinical utility of these algorithm‑based panels; laboratory certification (e.g., CAP/CLIA) does not substitute for demonstrated clinical benefit, and therefore the tests are considered investigational and not medically necessary.

    Definitions and Examples

    inv-10: Autoimmune disease diagnostic panel testing — definition
    DefinitionBlood-based testing that combines multiple serum- or cell-associated biomarkers with an interpretive score or proprietary algorithm intended to support evaluation of suspected systemic autoimmune disease (particularly systemic lupus erythematosus).
    Biomarkers includedMay include antinuclear antibodies (ANA), anti-dsDNA, anti-Smith, other disease-associated autoantibodies, soluble complement proteins, and cell-bound complement activation products.
    Reporting formatResults are generally reported as a composite score or tiered result intended to supplement, not replace, clinical assessment.
    Intended useSupport evaluation for diagnosis, differentiation, prognosis, risk stratification, or management of systemic autoimmune diseases, primarily SLE.
    LimitationsClassification criteria and laboratory certification do not substitute for evidence of clinical utility; clinician assessment with conventional serologic testing remains the basis for diagnosis.
    Policy Summary
    PayerAmeriHealth Caritas
    PolicyAutoimmune disease diagnostic panel testing
    Policy CodePolicy CCP.1562
    Change TypeNo material change
    Effective DateJul 1, 2026
    Next Review DateOct 1, 2027
    Key ActionExpect prior authorization requests for listed multianalyte/proprietary autoimmune panel codes to be denied as investigational/not medically necessary; document conventional serologic evaluation and clinical assessment when evaluating suspected systemic autoimmune disease.
    SourceLink
    On This Page
    Coverage DeterminationRelated CodesProvider Requirements and Administrative ActionsBackgroundDefinitions and Examples
    Documentation Required

    Document conventional serologic evaluation and clinical assessment

    Document a conventional serologic evaluation and clinical assessment when evaluating suspected systemic autoimmune disease; conventional testing commonly includes ANA, anti–double-stranded DNA, anti‑Smith, and complement protein testing along with clinical signs and symptoms.

    • Record results of antinuclear antibody (ANA) testing.
    • Record results of anti–double-stranded DNA and anti‑Smith antibody testing.
    • Record complement protein measurements and relevant clinical signs/symptoms.
    Denial Risk

    Denial risk — investigational autoimmune panel testing

    Requests for autoimmune disease diagnostic panel testing (including multianalyte assay panels, proprietary algorithm–based panels, AVISE-type panels, and cell-bound complement activation product panels) will be denied as investigational / not medically necessary for diagnosis, differentiation, prognosis, risk stratification, or management of autoimmune disease including SLE.

    inv-11: Examples of proprietary panels / codes
    0062UAutoimmune (systemic lupus erythematosus), IgG and IgM analysis of 80 biomarkers, utilizing serum, algorithm reported with a risk score.
    0312UAnalysis of 8 IgG autoantibodies and 2 cell-bound complement activation products using ELISA, flow cytometry, and indirect immunofluorescence; individual components reported with an algorithmic SLE-likelihood assessment.
    0446UAnalysis of 10 cytokine soluble mediator biomarkers by immunoassay, plasma; individual components reported with an algorithmic risk score for current disease activity.
    0447UAnalysis of 11 cytokine soluble mediator biomarkers by immunoassay, plasma; individual components reported with an algorithmic prognostic risk score for developing a clinical flare.
    81599Unlisted multianalyte assay with algorithmic analysis.